 SALT LAKE CITY, May 03, 2021 GLOBE NEWSWIRE -- Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property IP, including the Vectra test, from Myriad Autoimmunes business unit to Labcorp NYSE: LH for 150 million in cash. Labcorp is a leading global life sciences company and one of the nations largest laboratory service providers. 